Skip to main content
Top
Published in: Abdominal Radiology 7/2015

Open Access 01-10-2015

The influence of anti-TNF therapy on the magnetic resonance enterographic parameters of Crohn’s disease activity

Authors: Piotr Eder, Katarzyna Katulska, Iwona Krela-Kaźmierczak, Kamila Stawczyk-Eder, Katarzyna Klimczak, Aleksandra Szymczak, Krzysztof Linke, Liliana Łykowska-Szuber

Published in: Abdominal Radiology | Issue 7/2015

Login to get access

Abstract

Purpose

Magnetic resonance enterography (MRE) is a useful tool in assessing the transmural and extraintestinal lesions in Crohn’s disease (CD). However, the influence of anti-tumor necrosis factor (anti-TNF) therapy on MRE features of CD severity remains unknown. The purpose of the study was to assess the short- and long-term changes in MRE features of CD activity in relation to CD clinical course in patients treated with anti-TNF antibodies.

Methods

The influence on the most important parameters of CD activity seen in MRE was assessed retrospectively using a validated score. Patients were treated with anti-TNF agents and the clinical, laboratory, and MRE CD activity was estimated at baseline, after the induction therapy and after 1 year of treatment.

Results

71 patients were enrolled in a study. The change in CD clinical activity correlated significantly with fluctuations in MRE activity score (P < 0.0001, r = 0.5 for induction; P = 0.004, r = 0.7 for maintenance anti-TNF therapy, respectively). Bowel wall thickening, mesenteric lymphadenopathy, and fat wrapping with vascular proliferation were MRE parameters which changed significantly both after the induction and maintenance treatment in patients responding to the therapy. The change in MRE activity score was mostly pronounced during the first 3 months of treatment, when compared to the continuation of the therapy till week 52–54 (−6 points vs. −2 points, respectively; P = 0.0008).

Conclusions

Transmural and extraintestinal healing seen in MRE correlates with changes in CD clinical activity during anti-TNF therapy, thus MRE seems to be a useful tool in monitoring the efficacy of biological agents.
Literature
1.
go back to reference Amitai M, Ben-Horin S, Eliakim R, Kopylov U (2013) Magnetic resonance enterography in Crohn’s disease: a guide to common imaging manifestations for the IBD physician. J Crohns Colitis 7:603–615CrossRefPubMed Amitai M, Ben-Horin S, Eliakim R, Kopylov U (2013) Magnetic resonance enterography in Crohn’s disease: a guide to common imaging manifestations for the IBD physician. J Crohns Colitis 7:603–615CrossRefPubMed
2.
go back to reference Makanyanga JC, Taylor SA (2013) Current and future role of MR enterography in the management of Crohn’s disease. AJR Am J Roentgenol 1:56–64CrossRef Makanyanga JC, Taylor SA (2013) Current and future role of MR enterography in the management of Crohn’s disease. AJR Am J Roentgenol 1:56–64CrossRef
3.
go back to reference Feagan BG, Lemann M, Befrits R, et al. (2012) Recommendations for the treatment of Crohn’s disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis 1:152–160CrossRef Feagan BG, Lemann M, Befrits R, et al. (2012) Recommendations for the treatment of Crohn’s disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis 1:152–160CrossRef
4.
go back to reference Schill G, Iesalnieks I, Haimerl M, et al. (2013) Assessment of disease behaviour in patients with Crohn’s disease by MR enterography. Inflamm Bowel Dis 5:983–990CrossRef Schill G, Iesalnieks I, Haimerl M, et al. (2013) Assessment of disease behaviour in patients with Crohn’s disease by MR enterography. Inflamm Bowel Dis 5:983–990CrossRef
5.
go back to reference Dignass A, Van Assche G, Lindsay JO, et al. (2010) The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 4:28–62CrossRefPubMed Dignass A, Van Assche G, Lindsay JO, et al. (2010) The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 4:28–62CrossRefPubMed
6.
go back to reference Thia KT, Sandborn WJ, Lewis JD, et al. (2008) Defining the optimal response criteria for the Crohn’s disease activity index for induction studies in patients with mildly to moderately active Crohn’s disease. Am J Gastroenterol 103:3123–3131CrossRefPubMed Thia KT, Sandborn WJ, Lewis JD, et al. (2008) Defining the optimal response criteria for the Crohn’s disease activity index for induction studies in patients with mildly to moderately active Crohn’s disease. Am J Gastroenterol 103:3123–3131CrossRefPubMed
7.
go back to reference Daperno M, D’Haens G, van Assche G, et al. (2004) Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 60:505–512CrossRefPubMed Daperno M, D’Haens G, van Assche G, et al. (2004) Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 60:505–512CrossRefPubMed
8.
go back to reference Eder P, Katulska K, Lykowska-Szuber L, et al. (2013) Simple Enterographic Activity Score for Crohn’s Disease: comparison with endoscopic, biochemical, and clinical findings. Pol Arch Med Wewn 7–8:378–385 Eder P, Katulska K, Lykowska-Szuber L, et al. (2013) Simple Enterographic Activity Score for Crohn’s Disease: comparison with endoscopic, biochemical, and clinical findings. Pol Arch Med Wewn 7–8:378–385
9.
go back to reference Sandborn WJ, Hanauer S, van Assche G, et al. (2014) Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis 8:927–935CrossRefPubMed Sandborn WJ, Hanauer S, van Assche G, et al. (2014) Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis 8:927–935CrossRefPubMed
10.
go back to reference Tielbeek JA, Lowenberg M, Bipat S, et al. (2013) Serial magnetic resonance imaging for monitoring medical therapy effects in Crohn’s disease. Inflamm Bowel Dis 19:1943–1950PubMed Tielbeek JA, Lowenberg M, Bipat S, et al. (2013) Serial magnetic resonance imaging for monitoring medical therapy effects in Crohn’s disease. Inflamm Bowel Dis 19:1943–1950PubMed
11.
go back to reference Van Assche G, Herrmann KA, Louis E, et al. (2013) Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn’s disease. J Crohns Colitis 12:950–957CrossRef Van Assche G, Herrmann KA, Louis E, et al. (2013) Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn’s disease. J Crohns Colitis 12:950–957CrossRef
12.
go back to reference Ordas I, Rimola J, Rodriguez S, et al. (2014) Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology 146:374–382CrossRefPubMed Ordas I, Rimola J, Rodriguez S, et al. (2014) Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology 146:374–382CrossRefPubMed
13.
go back to reference Rimola J, Ordas I, Rodriguez S, Ricart E, Panes J (2012) Imaging indexes of activity and severity for Crohn’s disease: current status and future trends. Abdom Imaging 6:958–966CrossRef Rimola J, Ordas I, Rodriguez S, Ricart E, Panes J (2012) Imaging indexes of activity and severity for Crohn’s disease: current status and future trends. Abdom Imaging 6:958–966CrossRef
14.
go back to reference Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ (2013) Crohn’s disease complicated by strictures: a systematic review. Gut 7:1072–1084CrossRef Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ (2013) Crohn’s disease complicated by strictures: a systematic review. Gut 7:1072–1084CrossRef
15.
go back to reference Leal RF, Planell N, Kajekar R, et al. (2015) Identification of inflammatory mediators in patients with Crohn’s disease unresponsive to anti-TNFα therapy. Gut 64:233–242CrossRefPubMed Leal RF, Planell N, Kajekar R, et al. (2015) Identification of inflammatory mediators in patients with Crohn’s disease unresponsive to anti-TNFα therapy. Gut 64:233–242CrossRefPubMed
16.
17.
go back to reference Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. (2012) Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn’s disease. Gut 61:78–85PubMedCentralCrossRefPubMed Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. (2012) Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn’s disease. Gut 61:78–85PubMedCentralCrossRefPubMed
18.
go back to reference Olivier I, Theodorou V, Valet P, et al. (2011) Is Crohn’s disease creeping fat an adipose tissue? Inflamm Bowel Dis 3:747–757CrossRef Olivier I, Theodorou V, Valet P, et al. (2011) Is Crohn’s disease creeping fat an adipose tissue? Inflamm Bowel Dis 3:747–757CrossRef
Metadata
Title
The influence of anti-TNF therapy on the magnetic resonance enterographic parameters of Crohn’s disease activity
Authors
Piotr Eder
Katarzyna Katulska
Iwona Krela-Kaźmierczak
Kamila Stawczyk-Eder
Katarzyna Klimczak
Aleksandra Szymczak
Krzysztof Linke
Liliana Łykowska-Szuber
Publication date
01-10-2015
Publisher
Springer US
Published in
Abdominal Radiology / Issue 7/2015
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-015-0466-0

Other articles of this Issue 7/2015

Abdominal Radiology 7/2015 Go to the issue

Classics in Abdominal Imaging

The “pear-shaped” bladder

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.